Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients

Background: The biomarkers of immune checkpoint inhibitors (ICIs) efficacy and safety are still urgently needed. As cytokines are easily detected and monitored in circulation, they could be used as potential predictors of response and immune-related adverse events (irAEs) for ICIs therapy. Methods:...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Katarina Mirjačić Martinović, Ana Vuletić, Nevena Tišma Miletić, Irina Besu Žižak, Jelena Milovanović, Suzana Matković, Vladimir Jurišić
Format:	Artikel
Sprache:	English
Veröffentlicht:	Elsevier 2023-12-01
Schriftenreihe:	Translational Oncology
Schlagworte:	Metastatic melanoma patients BRAF wild type Pembrolizumab Cytokines Monitoring Outcome predictors
Online Zugang:	http://www.sciencedirect.com/science/article/pii/S1936523323001857

Ähnliche Einträge

Complete response in a patient with BRAF-mutant metastatic melanoma achieved with the multidisciplinary approach: a case report
von: Hana Garaj, et al.
Veröffentlicht: (2024-01-01)

Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices
von: Senar Ebinç, et al.
Veröffentlicht: (2023-09-01)

A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
von: Wu L, et al.
Veröffentlicht: (2021-02-01)

Increased circulating monocyte MDSCs positively correlate with serum Interleukin-10 in metastatic melanoma patients
von: Katarina Mirjačić Martinović, et al.
Veröffentlicht: (2023-04-01)

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives
von: Dugan MM, et al.
Veröffentlicht: (2024-07-01)

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
von: Polsky David, et al.
Veröffentlicht: (2004-12-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
von: Francesca Consoli, et al.
Veröffentlicht: (2020-07-01)

Case report: Exceptional disease progression in a 70-year-old patient: generalized melanosis and melanuria in the course of metastatic melanoma - a case study
von: Jacek Calik, et al.
Veröffentlicht: (2024-01-01)

Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease
von: Xiang Dan, et al.
Veröffentlicht: (2024-04-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
von: I. V. SAMOILENKO, et al.
Veröffentlicht: (2017-06-01)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma
von: Ernesto Rossi, et al.
Veröffentlicht: (2023-01-01)

A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [14C] encorafenib in healthy male subjects
von: Lance Wollenberg, et al.
Veröffentlicht: (2023-10-01)

Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report
von: Bartoušková Marie, et al.
Veröffentlicht: (2020-08-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
von: Justin C. Moser, et al.
Veröffentlicht: (2019-12-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
von: Yu. S. Shakh-Paronyants, et al.
Veröffentlicht: (2023-03-01)

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
von: Dahlia Fedele, et al.
Veröffentlicht: (2024-01-01)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
von: Saba S. Shaikh, et al.
Veröffentlicht: (2022-11-01)

Melanoma: BRAFi Rechallenge
von: Christoforos S. Kosmidis, et al.
Veröffentlicht: (2023-05-01)

Detection of humoral and cellular immune response to anti-SARS-CoV-2 BNT162b2 vaccine in breastfeeding women and naïve and previously infected individuals
von: Milena Cavic, et al.
Veröffentlicht: (2023-04-01)

MEK inhibitors for the treatment of NRAS mutant melanoma
von: Sarkisian S, et al.
Veröffentlicht: (2018-08-01)

The Human Melanoma Proteome Atlas—Complementing the melanoma transcriptome
von: Lazaro Hiram Betancourt, et al.
Veröffentlicht: (2021-07-01)

Current State of Target Treatment in BRAF Mutated Melanoma
von: Enrica Teresa Tanda, et al.
Veröffentlicht: (2020-07-01)

Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report
von: Marco Ghezzi, et al.
Veröffentlicht: (2020-03-01)

Limbic encephalitis in metastatic malignant melanoma patient induced by PD-1 checkpoint inhibitor pembrolizumab
von: Rozala Arko, et al.
Veröffentlicht: (2022-07-01)

Novel 5,6-dichlorobenzimidazole derivatives as dual BRAFWT and BRAFV600E inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations
von: Ahmed Temirak, et al.
Veröffentlicht: (2025-02-01)

p53 Promotes Cytokine Expression in Melanoma to Regulate Drug Resistance and Migration
von: Pinakin Pandya, et al.
Veröffentlicht: (2022-01-01)

Update on the treatment of BRAFmut metastatic melanoma and future perspectives
von: Peter Mohr, et al.
Veröffentlicht: (2025-03-01)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
von: Karam Khaddour, et al.
Veröffentlicht: (2021-06-01)

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study
von: Igor V. Samoylenko, et al.
Veröffentlicht: (2024-10-01)

Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma
von: Adi Kartolo, et al.
Veröffentlicht: (2022-03-01)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
von: Simeng Zhang, et al.
Veröffentlicht: (2023-01-01)

Rapidly progressing metastatic malignant melanoma mimicking primary pleural tumor: A case report
von: Clara So, et al.
Veröffentlicht: (2022-05-01)

Braf protein mutation and its significancy within patients with melanoma
von: Julia Kuchnicka, et al.
Veröffentlicht: (2022-08-01)

Treatment of Advanced Melanoma: Past, Present and Future
von: Taku Fujimura, et al.
Veröffentlicht: (2020-09-01)

Comparison of Two Rapid Assays for the Detection of <i>BRAF</i> V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes
von: Elodie Long-Mira, et al.
Veröffentlicht: (2022-03-01)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
von: Walid Shalata, et al.
Veröffentlicht: (2023-02-01)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
von: Nakul Dar, et al.
Veröffentlicht: (2023-08-01)

Tyrosine kinase inhibitors via nasogastric tube may resolve severe ileus secondary to melanoma: A case report
von: Lena Groennendijk, et al.
Veröffentlicht: (2022-06-01)

Association between braf gene mutation status and clinical-morphological features of cutaneous melanoma
von: O. I. Kit, et al.
Veröffentlicht: (2016-06-01)

Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome
von: Sim Vermeulen, et al.
Veröffentlicht: (2021-04-01)